Last reviewed · How we verify

Posaconazole powder for oral suspension

Merck Sharp & Dohme LLC · Phase 1 active Small molecule

Posaconazole powder for oral suspension is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development. Also known as: Noxafil.

At a glance

Generic namePosaconazole powder for oral suspension
Also known asNoxafil
SponsorMerck Sharp & Dohme LLC
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Posaconazole powder for oral suspension

What is Posaconazole powder for oral suspension?

Posaconazole powder for oral suspension is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes Posaconazole powder for oral suspension?

Posaconazole powder for oral suspension is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

Is Posaconazole powder for oral suspension also known as anything else?

Posaconazole powder for oral suspension is also known as Noxafil.

What development phase is Posaconazole powder for oral suspension in?

Posaconazole powder for oral suspension is in Phase 1.

Related